WebNational Center for Biotechnology Information WebMar 7, 2024 · When Dr. Gavathiotis and colleagues, led by co-first author Andrea Lopez, Ph.D., tested the drug duo against the 46 cell lines, it packed a one-two punch, with BTSA1.2 boosting active BAX to toxic levels in cancer cells, and Navitoclax acting as BAX’s bodyguard by preventing BCL-XL from neutralizing BAX. Limiting Side Effects
IJMS Free Full-Text Small-Molecule Inhibitors and Degraders ...
WebOct 9, 2024 · Dr. Gavathiotis was the lead author of a 2008 paper in Nature that first described the structure and shape of BAX’s activation site. He has since looked for small molecules that can activate BAX strongly enough to overcome cancer cells’ resistance to apoptosis. His team initially used computers to screen more than one million compounds … WebMar 7, 2024 · Gavathiotis is a co-founder and scientific advisor of BAKX Therapeutics, Inc. Studies were supported by the Pershing Square Sohn Cancer Research Alliance, NCI grant 2R01CA178394, and the Irma T ... grocery deals at walgreens
龚国华(博士生导师)_百度百科
WebMar 9, 2024 · Researchers at Albert Einstein College of Medicine have devised a promising strategy for overcoming a key cause of cancer deaths: the ability of cancer cells to thrive in the face of chemotherapy drugs designed to destroy them. There are cells, called cancer stem cells, that have the ability to evade chemotherapy and lie dormant for a while. Web2010年博士毕业于四川大学,获理学博士学位,博士期间主要进行天然产物治疗心血管疾病的药理学和代谢研究。 2010年至2013年在美国华盛顿大学(University of Washington )医学院对可在体监测单个线粒体功能的 “超氧炫(mitoflash)” 的发生机制和生理学意义进行研究。 WebEvripidis Gavathiotis, PhD is an assistant professor in the Departments of Biochemistry and Medicine of the Albert Einstein College of Medicine. Dr. Gavathoitis’ PhD training was in the areas of biological and biophysical chemistry at the University of Nottingham, followed by postdoctoral training in chemical and structural biology at the Rockefeller Univeristy and … figurines goodies lyon